



Supplementary figure S1. Flow diagram




Supplemental figure S2. Insulin doses (A, B) Insulin dose per Body weight (C, D) and changes in HbA1c after the switch from a rapid-acting insulin analog.


A. sitagliptin group




B. mitiglinide group



C. sitagliptin group




D. mitiglinide group



Supplemental figure S3. CPI and changes in glycated hemoglobin (HbA1c) after the switch from a rapid-acting insulin analog.

A. sitagliptin group



B. mitiglinide group

